Ambrilia has reported the termination of the phase III clinical Study 303. The move is in line with the company’s ongoing measures to effectively reduce costs.
Reportedly, study 303 involves clinical centers in both Europe and the US. The clinical study was designed to evaluate the 30mg, 20mg and 10mg dosage forms of Ambrilia’s octreotide acetate (C2L) in acromegalic patients.
The company said that it is continuing its regulatory filings process and discussions, utilizing the results from earlier studies completed namely – 301 and 302.
Ambrilia is a biotechnology company focused on the discovery and development of novel treatments for viral diseases and cancer.